International Biotechnology (LON:IBT) Shares Pass Above 200 Day Moving Average – Here’s Why

International Biotechnology (LON:IBT)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 690.81 ($8.54) and traded as high as GBX 733.88 ($9.07). International Biotechnology shares last traded at GBX 716 ($8.85), with a volume of 98,940 shares traded.

International Biotechnology Stock Performance

The company has a market cap of £268.68 million, a P/E ratio of 1,514.50 and a beta of 0.21. The company has a 50 day moving average price of GBX 701.04 and a 200-day moving average price of GBX 690.81. The company has a quick ratio of 0.32, a current ratio of 0.46 and a debt-to-equity ratio of 9.66.

International Biotechnology Increases Dividend

The firm also recently declared a dividend, which was paid on Friday, January 24th. Stockholders of record on Thursday, December 19th were paid a GBX 15.56 ($0.19) dividend. This is a boost from International Biotechnology’s previous dividend of $14.50. The ex-dividend date of this dividend was Thursday, December 19th. This represents a dividend yield of 2.21%. International Biotechnology’s dividend payout ratio is presently 6,041.67%.

Insider Transactions at International Biotechnology

In other news, insider Katherine Cornish-Bowden bought 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The stock was acquired at an average price of GBX 713 ($8.81) per share, with a total value of £10,695 ($13,216.76). Company insiders own 4.18% of the company’s stock.

About International Biotechnology

The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies.

The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.